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ABSTRACT
Aggressive meningiomas exhibit high levels of recurrence, morbidity and 
mortality. When surgical and radiation options are exhausted, there is need for novel 
molecularly-targeted therapies. We have recently identified NDRG4 overexpression in 
aggressive meningiomas. NDRG4 is a member of the N-Myc Downstream Regulated 
Gene (NDRG) family of the alpha/beta hydrolase superfamily. We have demonstrated 
that NDRG4 downregulation results in decreased cell proliferation, migration and 
invasion. In follow up to our prior studies; here we demonstrate that the predominant 
form of cell death following NDRG4 silencing is apoptosis, utilizing Annexin-V flow 
cytometry assay. We show that apoptosis caused by p53 upregulation, phosphorylation 
at Ser15, BAX activation, Bcl-2 and BcL-xL downregulation, mitochondrial cytochrome c 
release and execution of caspases following NDRG4 depletion. Sub-cellular distribution 
of BAX and cytochrome c indicated mitochondrial-mediated apoptosis. In addition, we 
carried out the fluorescence cytochemical analysis to confirm mitochondrial-mediated 
apoptosis by changes in mitochondrial membrane potential (Ψm), using JC-1 dye. 
Immunoprecipitation and immunofluorescence confirmed binding of NDRG4 to p53. In 
addition, we demonstrate that apoptosis is mitochondrial and p53 dependent. The 
proapoptotic effect of p53 was verified by the results in which a small molecule 
compound PFT-α, an inhibitor of p53 phosphorylation, is greatly protected against 
targeting NDRG4 induced apoptosis. These findings bring novel insight to the roles of 
NDRG4 in meningioma progression. A better understanding of this pathway and its 
role in meningioma carcinogenesis and cell biology is promising for the development 
of novel therapeutic targets for the management of aggressive meningiomas.
INTRODUCTION
Meningiomas represent one third of all primary 
central nervous system neoplasms [1]. They are the 
second most common brain tumors, and originate from the 
arachnoid “cap” cells of the arachnoid villi [2, 3]. While 
most meningiomas are benign, up to 15% are aggressive 
and characterized by a capacity for normal brain invasion 
with frequent and destructive recurrence patterns. 
Maximally safe surgical resection is the standard of care 
for all subtypes and grades of meningioma with adjuvant 
radiotherapy often used for aggressive tumor variants, or 
recurrent WHO Grade I tumors [4, 5]. WHO Grade II has 
a recurrence rate of greater than 40%, and WHO Grade III 
tumors recur over 80% of the time with death occurring 
within a decade after diagnosis [6, 7]. Malignant tumor 
progression depends upon the capacity of tumor cells 
to invade, metastasize and promote an angiogenic host 
response. Though surgery and radiation are important 
to therapy, there are few adjuvant therapies available 
to patients which are unresectable or recur. However, 
tumor growth rate following radiation therapy remains 
an intimidating clinical challenge with few effective 
alternative therapeutic options [8]. Alternative treatment 
options are required for patients with either malignant 
or recurrent benign meningiomas that are surgically 
inaccessible. There is a need for novel molecular targets 
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to improve survival and reduce morbidity for this group of 
patients. We recently showed that N-Myc down regulated 
gene 4 (NDRG4) was overexpressed in aggressive 
meningioma [9]. NDRG4 is involved in modulating cell 
proliferation, invasion, migration and angiogenesis in 
meningioma, and may play a valuable role as a molecular 
target in its treatment.
The N-Myc downstream-regulated gene (NDRG) 
family consists of NDRG1–4, these are identified as 
a novel class of Myc repressed intracellular proteins 
consisting of 340–394 amino acid residues with 57–65% 
sequence homology [10, 11]. The NDRG family proteins 
are members of the alpha/beta hydrolase super family; 
these α/β-hydrolases exhibit multiple surface hydrophobic 
residues that facilitate their molecular interactions [12]. 
Although the functional role in cellular progression has 
not yet been identified, NDRG4 have been identified as a 
novel interaction partner for Bves (Blood vessel epicardial 
substance). However, these protein-protein interactions 
have been mostly characterized in epithelial cells that 
influence epicardial cell movement [13]. NDRG proteins 
have also been implicated in development [11, 14], cancer 
metastasis [15, 16], and the immune system [17, 18]. 
Each of the four NDRG proteins demonstrates a distinct 
spatiotemporal expression pattern during embryonic 
development and in adult tissues [19, 20]. NDRG2 and 
NDRG4 are highly expressed in brain and heart [21] and 
promote neurite extension in PC12 neuronal cells [22, 23, 
24]. Recent literature suggests that NDRG2 interacts with 
p53 and regulates apoptosis in oxygen-glucose deprived 
C6-originated astrocytes [25]. This p53 interaction 
seems to be preserved in human lung, breast and brain 
malignancies [26].
NDRG4 has roles in development; including 
zebrafish myocyte proliferation [10] and normal brain 
development and function [27]. However NDRG4 also 
been identified as a tumor suppressor gene with NDRG4 
overexpression resulting in decreased colorectal cancer 
cell proliferation and invasion [28]. Most recently, 
NDRG4 has been found to be upregulated in glioblastoma, 
suggesting roles in cell cycle regulation and survival [29]. 
The relationship between NDRG4 and cell survival in 
meningioma is not established yet in vivo but knockdown 
of NDRG4 decreases migration, invasion and inhibited 
cell cycle progression in meningioma cells [9].
Cell proliferation and apoptotic cell death are very 
complex processes that involve the participation of a host 
of genes. In both events, p53 is one of the most important 
and studied tumor suppressor genes [30]. P53 maintains 
tumor suppression by transcriptional regulation of genes 
involved in cell growth and apoptosis [31]. Elevated 
levels of p53 are observed in malignant meningiomas 
and overexpression of p53 is associated with high 
levels of cellular proliferation, rapid tumor recurrence 
and radioresistance [32]. The p53 tumor suppressor 
protein mediates a range of mitochondria mediated 
apoptotic responses initiated by various external and 
internal stimuli [33]. The fundamental consequences of 
mitochondrial-mediated apoptosis include the unstablised 
mitochondrial membrane integrity, cytochrome c 
release and the activation of Bcl-2 family proteins [34]. 
BAX, a pro apoptotic protein is mainly localized in the 
cytoplasm and translates into mitochondria in response 
to apoptotic stimuli [35]. The extrinsic pathway of 
apoptosis requires the cytochrome c release from the 
mitochondrial intermembrane space to the cytosol [36]. 
Once released, cytochrome c cooperates with the adaptor 
protein, APAF-1, to promote the activation of caspases, 
which are required for the rapid recognition, triggers DNA 
fragmentation and clearance of the abnormal cells [37].
Our research involves the discovery of targets 
that would enhance the effects of meningioma cancer 
treatment. RNA interference-based, targeted silencing 
of gene expression is a strategy of potential interest for 
cancer therapy [38]. Currently, attempts are being made to 
overcome the adverse effects and limitations of radiation-
resistant tumor cells using the gene therapy [39]. However, 
the detailed contribution of the NDRG4 protein and its 
biological significance in malignant meningiomas has not 
been studied. The mechanism of action of the depleted 
NDRG4 induced cell death was unknown. In the present 
study, to better characterize the key roles of NDRG4 in 
vitro, we have used a lentiviral vectors expressing small 
hairpin RNA directed against NDRG4. We demonstrate for 
the first time that downregulation of NDRG4 gene activates 
p53 by phoshorylation at Ser15, increased BAX expression 
and translocation into mitochondria, which leads to 
destabilization of mitochondria which has ultimately induces 
the activated caspase mediated apoptosis in meningioma 
tumor cells. It is clear that the understanding of NDRG4 
function in the development of meningioma pathology may 
give new insights in future therapeutic strategies including 
gene therapy. Hence, selectively targeting NDRG4 with 
lentiviral mediated gene silencing may be a potential cancer 
therapy for malignant meningiomas.
RESULTS
Knockdown of NDRG4 regulates cell proliferation 
and induces the apoptosis in meningioma
To evaluate the role of NDRG4 in cell proliferation 
and cell death in meningioma cells, NDRG4 was targeted 
in IOMM-Lee and CH-157 MN cells using specific 
lentiviral shRNA vectors. IOMM-Lee and CHMN-157 
are the most frequently used and well characterized 
high-grade meningioma cell lines. Knockdown of 
NDRG4 gene was confirmed using immunoblots after 
viral purification. Targeting of NDRG4 significantly 
decreased proliferation rates in both IOMM-Lee 
(74.93%, p = 0.1072) at 24 hrs, 63.0%, p = 0.0048 at 
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48 hrs and 38.15%, p = 0.0002 at 72 hrs) and CH-157 
MN (71.51%, p = 0.0108 at 24 hrs, 56.65%,  p = 0.0001 
at 48 hrs and 42.65%, p = 0.0002 at 72 hrs) compared 
to control cells. In both the cell lines targeting NDRG4 
significantly decreased proliferation (Figure 1A). We 
further analyzed these cells for apoptosis using Annexin 
V- APC assay. Knockdown of NDRG4 induced 43.2% 
of early apoptosis and 18.4% of late apoptosis in the 
IOMM-Lee cells and 4% early apoptosis and 29.4% 
late apoptosis in the CH MN-157 cells was detected. 
Targeting NDRG4 significantly induced apoptosis in 
both IOMM-Lee (65%; p = 0.0001) and CH-157 MN 
cells (31%; p = 0.0061) when compared to control cells 
(Figure 1B). These results indicate that NDRG4 regulated 
proliferation and prevented apoptosis in IOMM-Lee and 
CH-157 MN cells.
NDRG4 regulates apoptotic signaling in 
meningioma cells
To determine the role of NDRG4 in the molecular 
mechanism of apoptosis, we analyzed mitochondrial 
Bcl-2 family protein expression in presence or absence 
of NDRG4 in meningioma cell lines by western 
Immunoblotting, 72 hrs post infection. Targeting 
NDRG4 in IOMM-Lee cells and CH-157 MN cells led 
to increased accumulation of pro apoptotic protein BAX 
and decrease in anti-apoptotic proteins Bcl-2 and Bcl-
xL. Targeting of NDRG4 also led to increased caspase 9, 
caspase 3 and PARP 1 activity (Figure 2A). We further 
validated the caspase 9 activity by calorimetric assay 
and observed a two-fold increase of caspase 9 activity in 
NDRG4 knockdowned cells than the control vector and 
untransduced cells (Figure 2B). These results indicate 
induction of intrinsic like apoptosis in the absence of 
NDRG4 in meningioma cells.
Targeting the NDRG4 induces mitochondrial-
mediated apoptosis
To determine the role of NDRG4 in mitochondrial-
mediated apoptosis, we analyzed the mitochondrial 
and cytosolic fractions in NDRG4 knockdowned and 
control IOMM-Lee and CH-157 MN cells. We observed 
increased BAX and decreased cytochrome c expression 
in mitochondrial fractions of NDRG4 knockdowned 
cells when compared to control cells (Figure 3A). 
Correspondingly we observed that there was increased 
BAX and decreased cytochrome c expression in 
cytoplasmic fractions in control cells when compared 
to NDRG4 kncockdowned cells. These results suggest 
that BAX translocates to the mitochondria and releases 
cytochrome c to the cytosol leading to induction of 
intrinsic like apoptosis. Analyzing the lysates with COX 
IV and GAPDH checked the purity of the fractions. 
Since mitochondrial membrane potential (Ψm) damage 
is a key event that causes the activation of caspases, 
cytochrome c release into cytosol. We determined the 
Ψm using cytofluorometric lipophilic cationic dye, 
JC-1 by confocal microscopy. We observed more JC-1 
aggregates (red fluorescence) in NDRG4 targeted cells 
at 24 hrs, however at later time points (72 hrs), JC-1 
Figure 1: Knockdown of NDRG4 decreases the cell viability and induces the apoptosis. A. IOMM-Lee and CH-157 MN cells were 
infected with viruses generated in HEK 293T cells transfected with Control vector (CTR) or NDRG4 (shND) specific shRNA. Equal numbers of 
IOMM-Lee and CH-157 MN cells were plated in 96-well plates after gene silencing. After 24 hrs, 48 hrs and 72 hrs, cells were treated with MTT and 
the cell viability was determined using a colorimetric cell proliferation assay. Shown is the percent viability. Error bars indicate SEM (*p < 0.05, 
n = 3). B. Suppression of NDRG4 gene expression induces apoptosis in IOMM-Lee and CH-157 MN cells. IOMM-Lee and CH-157 MN cells 
were infected with lentivirus generated in HEK 293T cells transfected with Control vector or NDRG4 specific shRNA. 72 hrs of post transduction, 
untreated (UT), control (CTR) and shNDRG4 (shND) treated cells were stained with Annexin V-APC/propidium iodide and analyzed by flow 
cytometry. The graph indicating the percent apoptosis for each treatment group is shown SEM of triplicates. *p < 0.05.
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Figure 3: A. Subcellular distribution of BAX and cytochrome c. IOMM lee and CH-157 MN cells were infected with lentivirus 
generated in HEK293T cells transfected with control vector or NDRG4 specific shRNA. 72 hrs of post transduction, untreated, control and 
shNDRG4 treated cytosolic (40 μg) and mitochondrial (40 μg) protein fractions were immunoblotted-using antibodies to cytochrome c and BAX. 
GAPDH and COX IV were used to determine loading in cytosolic and mitochondrial fraction respectively. B. Mitochondrial membrane potential 
damage (ΔΨm). Mitochondrial membrane potential damage was evaluated using JC-1 reagent. To determine the initiation of mitochondrial 
apoptosis IOMM-Lee cells were infected with lentivirus generated in HEK 293T cells transfected with control vector or NDRG4 specific shRNA. 
After 24 hrs, 48 hrs 72 hrs and 96 hrs of post transduction, untreated, control and shNDRG4 treated cells were collected and stained with JC-1 
fluorescence dye and images were captured with confocal microscopy. We carried out Immunofluorescence analysis of mitochondrial membrane 
potential by JC-1 staining for decreased red fluorescence (JC-1 aggregates) and increased green fluorescence (JC-1 monomers).
Figure 2: Silencing NDRG4 induces apoptosis through the mitochondrial apoptotic pathway. A. IOMM-Lee and 
CH-157 MN cells were infected with lentivirus generated in HEK 293T cells transfected with control vector or NDRG4 specific shRNA. 
The knockdowned cells were lysed using RIPA/MPER buffer. 40 μg cell lysate of mitochondrial apoptotic proteins: BAX, BcL2, 
BcL-xL, cleaved Caspase 9, cleaved Caspase 3 and PARP I were immunoblotted. B. Caspase 9 enzyme activity assay. IOMM lee and CH-157 
MN cells were infected with viruses generated in HEK 293T cells transfected with control vector or NDRG4 specific shRNA. 72 hrs of post 
transduction, untreated, control and shNDRG4 treated cells were lysed using RIPA/MPER and 40 μg of cell lysate were incubated with a 
LEHD-pNA substrate. Caspase 9 activity was measured at 405 nm. The graph indicating the OD at 405 nm for each treatment group is shown 
in triplicates. Error bars indicate SEM (*p < 0.05, n = 3).
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aggregates were diminished and JC-1 monomers (green 
fluorescence) increased in the cytosol (Figure 3B). 
At 96 hrs, both the monomeric form and dimeric forms 
were diminished due to apoptosis. NDRG4 targeted 
cells showed loss of mitochondrial membrane potential 
indicating mitochondrial depolarization. These results 
suggest that NDRG4 plays a vital role in maintaining 
mitochondrial membrane potential and preventing 
apoptosis in meningioma cells.
NDRG4 directly regulates p53 activity
NDRG proteins directly or indirectly associate 
with variety of other proteins and activate intracellular 
signaling pathways [13, 25, 40]. We investigated the 
protein levels of various pro-apoptotic proteins like 
p53, p21 and phospho-p53 Ser15 by western blotting. 
Targeting NDRG4 led to activation of p53 (Ser15) and 
stabilization of total p53 in both IOMM-Lee cells and 
CH-157 MN cells when compared to control cells 
(Figure 4A). Total p21 in NDRG4 targeted and control 
cells remained unaltered. These results indicate that 
p53 induces apoptosis in meningioma cells when 
NDRG4 is knockdowned. Since p53 was activated in 
NDRG4 targeted cells, we wanted to determine if there 
was a direct interaction between p53 and NDRG4. We 
performed an Immunoprecipitation assay to test for 
NDRG4 and p53 molecular interactions. Protein lysates 
of IOMM-Lee and CH-157 MN cells in the presence 
and absence of NDRG4 were immunoprecipated with 
NDRG4 antibody and probed for p53 and NDRG4 by 
western blotting (Figure 4B). Western immunoblotting 
revealed that NDRG4 indeed interacted directly with 
p53 and that p53 was present only in the control and 
Figure 4: A. Knockdown of NDRG4 enhances p53 activity. IOMM-lee and CH-157MN cells were infected with viruses generated 
in HEK 293T cells transfected with Control vector or NDRG4 specific shRNA. The knockdowned cells were lysed using RIPA/MPER and 
40 μg of cell lysates were immunoblotted for total p53, phospho p53 (Ser 15) and p21 protein levels. GAPDH was used to determine protein 
loading. B. NDRG4 directly interacts with p53. IOMM-lee and CH-157 MN cells were infected with lentivirus generated in HEK 293T 
cells transfected with control vector or NDRG4 specific shRNA. 72 hrs of post transduction, untreated, control and shNDRG4 treated total 
cellular protein fractions were Immunoprecipitated-using antibodies to-NDRG4 and probed with p53 antibody. C. P53 and NDRG4 co-
localization. Immunocytochemical colocalization of NDRG4 and p53 in IOMM-Lee and CH 157-MN control cells. NDRG4 is conjugated 
with Alexa Fluor 594 secondary antibody. P53 is conjugated with Alexa Fluor 488 secondary antibody. Co-localization of NDRG4 and p53 
was detected in IOMM-Lee and CH 157 MN control cells. All experiments were performed in triplicate (n = 3). D. Subcellular localization 
of NDRG4. IOMM lee and CH-157 MN cells were infected with lentivirus generated in HEK293T cells transfected with control vector or 
NDRG4 specific shRNA. 72 hrs of post transduction, untreated, control and shNDRG4 treated nuclear fraction (NF) (40 μg) and cytosolic 
fraction (CF) (40 μg) protein fractions were immunobltted-using antibodies to NDRG4. Lamin A/C and PCNA were used to determine 
loading in nuclear fraction.
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untransduced lysates and absent in NDRG4 targeted 
lysates. Further we performed immunocytochemical 
staining of p53 and NDRG4 in IOMM-Lee and CH157 
MN cells. Immunocytochemical analysis showed 
expression of both p53 (green) and NDRG4 (red) 
in IOMM-Lee and CH157 MN cells (Figure 4C). 
The overlay images revealed co-localization of 
p53 and NDRG4 (Figure 4C). In the fluorescence 
Immunocolocalization analysis of p53 and NDRG4, we 
observed the nuclear expression of NDRG4 in both the 
cell lines. To confirm the nuclear localization of NDRG4 
we analyzed the NDRG4 protein levels in the nuclear 
and cytosolic extracts of NDRG4 knockdown and control 
cells by Immunoblotting (Figure 4D). Analyzing the 
lysates with Lamin A/C and PCNA checked the purity 
of the nuclear fractions. We observed NDRG4 protein 
expression in both the nuclear and cytosolic fractions of 
control cells rather than the cells knockdown of NDRG4. 
Comparatively with nuclear NDRG4, cytosolic NDRG4 
protein expression was high in both IOMM-Lee and CH 
157 MN cells. These results indicate that there is a direct 
interaction between NDRG4 and p53 predominantly in 
the cytosol.
Inhibition of p53 attenuates NDRG4 targeted 
mitochondrial-mediated apoptosis
Since we observed induction and stabilization of p53 
in the absence of NDRG4 and also detected direct interaction 
between NDRG4 and p53, we wanted to determine if 
p53 played a direct role in NDRG4-mediated apoptosis 
in meningioma cells. We inhibited p53 using PFT-α and 
analyzed apoptosis in meningioma cells in the presence and 
absence of NDRG4. Targeting NDRG4 significantly induced 
the apoptosis in both IOMM-Lee cells (43%; p = 0.0366) and 
CH-157 MN (33%; p = 0.0275) when compared to controls 
(Figure 5A). Inhibition of p53 by PFT-α (10 μM) abrogated 
the shNDRG4 induced apoptosis in IOMM-Lee (11%; p = < 
0.05) and CH-157 MN (11%; p < 0.05) cells (Figure 5A). To 
evaluate the role of p53 in the absence of NDRG4 induced 
apoptosis, cells were pre-treated with Pifithrin-α (PFT-α) in 
the various conditions, and analyzed by Western blotting. 
Western immunoblots showed activation of p53 when 
NDRG4 was targeted in both IOMM-Lee and CH-157 MN 
cells (Figure 5B), and this activation was abrogated when 
p53 was inhibited with PFT-α (10 μM). Taken together these 
results indicate that inhibition of p53 prevented mitochondrial 
apoptosis in NDRG4 targeted meningioma cells.
DISCUSSION
The management of recurrent and high grade 
meningiomas remains a challenge. The key is to elucidate 
disease mechanisms, validate therapeutic targets, and 
develop new therapeutic strategies. We believe that our 
studies evaluating the role of NDRG4 in meningioma 
biology are important for meeting that challenge.
Figure 5: Inhibition of p53 abrogates targeted NDRG4 induced apoptosis. IOMM-lee and CH-157 MN cells were infected 
with lentivirus generated in HEK 293T cells transfected with control vector or NDRG4 specific shRNA. PFT-α (10 μM) was added to the 
cells after 4 hrs of infection. 72 hrs of post transduction, untreated, control and shNDRG4 treated cells were stained with Annexin V-PE/ 
7-AAD and analyzed by flow cytometry. A. The graph indicating the percentage of apoptosis for each treatment group is shown SEM of 
triplicates. *p < 0.05. B. 40 μg of the above shNDRG4 ± PFT-α treated cell lysate were immuno blotted with NDRG4 and Phospho p53 
(Ser15). Beta actin was used to determine protein loading.
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NDRG4 plays varied roles in tumor suppression 
and progression in various cancers [29] [28, 41]. In our 
previous studies, we demonstrated that NDRG4 was 
overexpressed in IOMM-Lee and CH-157 MN cells and 
NDRG4 silencing inhibited cell proliferation, motility, 
invasion and angiogenesis in high grade meningioma 
cell lines [9]. In this study we demonstrate the molecular 
mechanisms of cell death associated with NDRG4 gene 
knockdown.
Proliferation and apoptotic cell death are complex 
processes involving many genes. Given the increased 
expression levels in aggressive meningiomas, studies were 
best undertaken first with NDRG4 protein depletion. We 
utilized lentiviral-mediated short hairpin RNA interference 
(52 MOI) to knockdown expression of NDRG4. In this 
manner, we demonstrated robust cellular death upon 
NDRG4 gene knockdown within the IOMM-Lee and 
CH-157 MN cell lines. NDRG4 gene knockdown 
significantly induced apoptosis as determined by FACS 
analysis (Figure 1B). This cell death was in the form of 
apoptosis as seen in GBM [29], and we proceeded to 
characterize the form of apoptosis.
Mitochondria represent the central checkpoint 
in apoptotic signaling [42, 43, 44]. Following NDRG4 
silencing, we observed loss of mitochondrial membrane 
potential in NDRG4 targeted IOMM-Lee and CH-157 
MN cell lines (Figure 3B), consistent with membrane 
depolarization. We then characterized the signaling 
associated with mitochondrial dependent apoptosis. 
NDRG4 gene knockdown resulted in decreased 
expression of Bcl-2 and BcL-xL, translocation of 
activated BAX into the mitochondria, cytochrome c 
release and enhanced cleaved caspase expression in 
meningioma cells (Figure 3A).
P53 overexpression is reported in several human 
malignant tumors [45] and elevated levels of wild type 
p53 are observed in aggressive malignant meningiomas 
[32]. P53 mediated BAX activation and induction of 
caspases, and apoptosis execution has been identified 
in multiple diseases including cancer [46, 47, 48]. 
Moreover, p53 has been linked to the mitochondrial 
intrinsic like apoptotic pathway by novel transcription-
independent interactions with antiapoptotic and 
proapoptotic members of the Bcl-2 family proteins 
[49, 50]. Activated p53 can induce the expression 
of p21, which participates in cell cycle arrest, BAX 
expression, mitochondrial membrane potential damage 
and activation of caspases that lead to apoptosis [51]. 
In NDRG4 depleted meningioma we observed increased 
p53 activity and stabilization which activated effector 
caspases by releasing mitochondrial cytochrome c into 
the cytoplasm. NDRG4 gene knockdown induced 
apoptosis was associated with p53 phoshorylation at 
Ser15 without a change in total p53 or p21 expression 
levels (Figure 4A). Similar data showing apoptotic cell 
death was reported in embolized meningiomas [52].
NDRG4 gene knockdown results in BAX translocation 
in an indirect manner. According to the existing reports on 
the p53 intrinsic apoptotic pathway, phosphorylated p53 
induces the BAX stimulation [53, 54]. Bcl-2 inhibits BAX 
dimerization and translocation into mitochondria. In our 
studies we have identified Bcl-2 inhibition (Figure 2) in the 
absence of NDRG4. These indirect downstream signaling 
of apoptotic response is mediated by p53. However, 
p53 is activated after the dissociation from NDRG4. We 
demonstrate that p53 activation occurs in the absence of 
NDRG4 (Figure 4A), that there is a direct interaction between 
NDRG4 and p53. These results were clearly showed in the 
protein-protein interaction studies (Figure 4B, 4C). However, 
there is much data demonstrating mitochondrial dependent 
apoptotic signaling downstream of p53 activation. In terms of 
BAX translocation and its mechanism [53] and downstream 
apoptosis signaling [54, 55].
NDRG4 gene knockdown results in intrinsic like 
apoptosis and our data suggest that this is p53 dependent. 
Similar reports of NDRG proteins roles in p53 mediated 
apoptosis are present in various cancers [25, 26, 56]. 
We demonstrated that p53 and NDRG4 co-localize, 
and immunoprecipitation experiments show p53 in the 
lysates of controls cells but not in the NDRG4 depleted 
lysates (Figure 4B, 4C). This suggests a possibly direct 
role of NDRG4 in interaction with p53 and indirect role 
in downstream signaling of apoptotic response. Further 
we have demonstrated the subcellular levels of NDRG4 
(Figure 4D) because of nuclear localization of NDRG4 was 
observed in the fluorescence colocalization studies. These 
resulted confirmed the nuclear and cytoplasmic localization 
of NDRG4. Whereas p53 and NDRG4 interaction was much 
observed in the cytoplasm (Figure 4C). We believe that 
the cytoplasmic NDRG4 and p53 interaction was playing 
a crucial role in the regulation of apoptosis. In addition, 
we demonstrated that NDRG4 depleted meningioma cells 
treated with Pifitrhin-α which inhibits p53 activity, observed 
the significant inhibition of apoptotic cell death by Annexin 
-V assays. Furthermore, protein expression analysis of 
Phospho-p53 in PFT-α treated cells in the presence or 
absence of NDRG4 confirmed the role of p53 activity in 
triggering the apoptotic signal.
In summary, this is the first report demonstrating that 
NDRG4 silencing induces apoptotic cell death in aggressive 
meningioma cell lines. These findings advance our 
understanding of the role of NDRG4 in tumor progression; 
suggest a role for NDRG4 as a novel oncogenic protein, and 
as a potential therapeutic target for a difficult disease.
MATERIALS AND METHODS
Cells lines and chemicals
Human meningioma cancer cell lines IOMM-Lee 
and CH-157 MN were kindly provided by Dr. Yancie 
Gillespie, University of Alabama in Birmingham and Dr. 
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Anita Lal – University of California, San Francisco and 
grown in DMEM, DMEM/F12 media containing 10% 
fetal bovine serum and 1% penicillin/streptomycin. All 
cell lines were maintained in a 37°C incubator in a 5% 
CO2-humidified atmosphere.
NDRG4 specific shRNA sequence (CAAACTAT 
GCTTCAACACCTT) and control shGFP sequence (CGAC 
GTAAACGGCCACAAGTT) cloned into a lentiviral 
packaging vector (pLKO.1) were obtained from the Genome 
Institute at the Washington University School of Medicine in 
St Louis, USA. Lentiviral packaging (pCMVdR8.2dvpr) and 
envelope (pCMV-VSV-G) vectors and were obtained from 
Adgene, Cambridge, MA. Antibodies to NDRG4 (39) V: 
sc-100788, p53 (D)-1): sc-126, p53 (3H2821): sc-56179), 
p53 (FL-393) sc-6243, p21 (F5): sc-6246, BAX(N20): 
sc-493, BAX(B-9): sc-7480, Bcl-xL (H-5): sc-8392, Bcl-
2 (N-19): sc-492, PARP-1 (H-250): sc-7150, β-Actin 
(c4); sc-47778, GAPDH(A-3): sc-137179 and Pifitrhin-α 
were obtained from Santa Cruz Biotechnology . Anti-p53 
(ab2433) was purchased from Abcam. p53(1C12) Mouse 
mAb #2524, Phospho-p53 (Ser15) (16G8) Mouse Ab #9286, 
Caspase-9 (mouse specific) #9504, cleaved Caspase-3 
(Asp175) #9661, COX IV antibody #4844 and Anti Rabbit 
HRP-linked IgG #7074B were obtained from Cell Signaling. 
Alexafluor 488 anti mouse-Ab, was from Invitrogen. HRP 
Goat anti-mouse IgG antibody was from BioLegend.
Lentiviral transduction and knockdown of 
NDRG 4 in meningioma cell lines
Recombinant lentiviral particles were produced 
in HEK293-T cells by co-transfecting lentiviral (LV) 
plasmid containing NDRG4 or control shRNA, along with 
the packaging vector pCMVdR8.2dvpr, and a plasmid 
encoding the vesicular stomatitis virus coat envelope 
pCMV-VSV-G. Lentiviral purification and infection of 
target cells were done as described earlier [57, 58]. Briefly 
IOMM-Lee and CH-157 MN cells were infected with 
medium containing virus (shNDRG4 or control shRNA) 
along with Polybrene (8 μg/ml) to enhance infectivity 
(16 hrs). A multiplicity of infection (MOI) of 52 was 
used for our experiments. Cells were washed with PBS 
and replenished with regular growth medium for 48–72 
hrs. The transduced cells were selected by using 2 μg/ml 
Puromycin [9].
Cell proliferation assay
Cell proliferation was evaluated using the 
3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium 
bromide dye method. Equal numbers (20, 000) of IOMM-
Lee and CH MN 157 cells were seeded in a volume of 
100 μL in each well of 96-well plate for 24 hrs. Cells 
were infected with viruses generated in HEK293T cells 
transfected with GFP or NDRG4 specific shRNA for 
24 hrs, 48 hrs and 72 hrs. After incubation, MTT was 
added into each well to a final concentration of 5 mg/ml. 
The insoluble Formosan was collected and dissolved in 
dimethylsulfoxide (DMSO, 0.5%) and absorbance was 
measured at 570 nm (Bio-Tek,).
Immunoblot analysis
The treated cells were washed with PBS, and lysed 
using M-PER mammalian protein extraction reagent 
with protease inhibitor cocktail. The lysates were 
homogenized by sonication and protein concentration 
was determined using the BCA protein assay reagent. 
Cellular protein (40 μg) was separated using 10–14% 
SDS- PAGE and transferred onto PVDF membranes. 
Proteins were analyzed with specific primary antibodies 
and developed using a horseradish peroxidase-conjugated 
anti rabbit or anti-mouse IgG secondary antibody. 
Specific proteins were detected with western lighting 
Plus - ECL and using Bio-Rad Image lab images were 
scanned.
Isolation of nuclear and cytosolic extracts
Nuclear and cytosolic extracts from the treated 
cells were isolated using Chemicon International 
nuclear extraction kit. Cells were washed once with 
1X ice cold PBS, the cell pellet was resuspended in 1X 
cytosolic lysis buffer and incubated on ice for 15 min 
and homogenized the cells using 20–25 times with 27 
gauge needle syringe. The lysates were centrifuged at 
8000 g for 20 min at 4oC. The supernatant that included 
the cytosolic portion of the cell lysate was collected. The 
remaining pellet containing the nuclear portion of the 
cell lysates were suspended in ice cold nuclear extraction 
buffer and homogenized. The nuclear suspension was 
centrifuged at 16000 g for 5 min at 4oC to collect the 
nuclear fraction. Immunoblot analysis was performed 
with the cytoplasmic and nuclear fractions for proteins 
like NDRG4, Lamin A/C and PCNA.
Isolation of mitochondrial and cytosolic extracts
Mitochondrial and cytosolic extracts from 
the treated cells were isolated using Active Motif 
mitochondrial fractionation kit. Cells were washed once 
with 1X ice cold PBS, the cell pellet was resuspended 
in 500 μl of 1X cytosolic buffer incubated for 15 
min at 4°C on a rocking platform and homogenized 
the cells using 20–25 times with 0.5 ml syringe. The 
lysates were centrifuged at 3000 rpm for 20 min at 
4oC. The supernatant that included the cytosolic and 
mitochondrial fraction was collected. The supernatant 
was centrifuged at 10,000 rpm for 20 minutes at 4°C 
to separate the mitochondria as a pellet and cytosolic 
fraction as the supernatant. The Mitochondrial pellet 
was washed with 100 μl 1X cytosolic buffer and 
centrifuged at 10,000 rpm for 10 min at 4°C to collect 
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the mitochondrial pellet and dissolved in 100 μl of 
complete mitochondrial buffer. Immunoblot analysis 
was performed with the cytoplasmic and mitochondrial 
fractions for proteins like BAX, COX IV, Cytochrome 
C and GAPDH.
Mitochondrial membrane potential damage
IOMM-Lee cells (2 × 105) were infected 
with lentivirus containing shNDRG4 for 24 hrs, 
48 hrs, 72 hrs and 96 hrs. Cells were then stained 
with 2.5 μM JC-1 (5, 5, 6, 6-tetrachloro-1, 1, 3, 3- 
tetraethylbenzimidazolylcarbocyanineiodide, Cayman 
Chemicals) for 30 min at 37°C, and Digital pictures 
for JC monomers (Green fluorescence; 535 nm) and JC 
aggregates (red fluorescence; 570 nm ) were captured by 
confocal microscope (Zeise LSM 510).
Immunoprecipitation
Cell lysates (400 μg) from shGFP and shNDRG4 
transduced cell lines were incubated with NDRG4 specific 
antibody (2 μg) overnight at 4°C. Following incubation 
30 μl of protein G coupled magnetic beads (MACS) were 
added to antibody conjugated protein and incubated for 
30 min on ice. The immunoprecipitated protein lysate 
complex was then added to the pre-equilibrated micro 
columns (miltenybiotec) and washed with lysis buffer 
and eluted with 1X SDS sample buffer containing 
β-Mercaptoethanol at 90°C. The Immunoprecipitated 
protein was resolved on SDS-PAGE and immunoblotted 
for p53 and NDRG4.
Immunocytochemical co-localization analysis
IOMM-Lee and CH-157 MN cells (5000) 
seeded on 4-well chamber slides were fixed with 4% 
paraformaldehyde and incubated with 1% bovine serum 
albumin in PBS at room temperature for 30 min. Cells 
were washed with PBS, and incubated overnight with 
primary antibodies (1:100), at 4°C. Cells were then washed 
with PBS, and incubated with secondary antibodies for 
1 hr at room temperature. The cells were then washed, 
and mounted with an anti-fade reagent containing DAPI 
and fluorescent photomicrographs were then obtained by 
confocal microscope (Zeiss LSM 510).
Caspase-9 activity assay
A quantitative Caspase 9 enzyme activity assay 
was performed using Caspase 9 assay kit (Bio-vision). 
Cell lysates (200 μg) were incubated with 50 μl 
of 2X reaction buffer and 5 μl of the 4 mM LEHD-
pNA substrate and incubated at 37°C for 1–2 hrs. 
The caspase activity was measured as the pNA light 
emission at 405-nm.
Apoptosis assay
Apoptosis was determined using apoptosis 
detection kit (BD Pharmingen, USA). Cells (100,000) 
were incubated with Annexin V-APC/PE and propidium 
iodide/7-AAD for 15 min at room temperature. The cells 
were then analyzed by flow cytometry, using a two-color 
FACS analysis system (BD LSR II). For each treatment, 
the average fold-increase of apoptotic cells over control 
was calculated.
Statistical methods
Statistical analysis and graphical presentation was 
done using quantitative data from MTT assay, FACS 
analysis and other assays were evaluated for statistical 
significance using GraphPad Prism 4.0. Data for each 
treatment group were represented as means ± SEM and 
compared with other groups for significance by one-
way ANOVA. Results presented in this study are the 
representative images of three independent experiments 
(n = 3) and results are expressed as mean ± SEM. and 
differences were considered significant at a p value of less 
than 0.05.
ACKNOwLEDGMENTS
We thank the Genome Institute at the Washington 
University School of Medicine in St Louis for providing 
the lentiviral shRNA constructs for the Gene knockdown 
experiments. NDRG4 specific shRNA sequence 
(CAAACTATGCTTCAACACCTT) gene source 65009, 
Clone name NM_020465.1-301s1c1. Control vector gene 
sequence (CGACGTAAACGGCCACAAGTT) cloned 
into a lentiviral packaging vector (pLKO.1).
REFERENCES
1. Perry A, Scheithauer BW, Stafford SL, Lohse CM, Wollan 
PC. “Malignancy” in meningiomas: a clinicopathologic 
study of 116 patients, with grading implications. Cancer. 
1999; 85:2046–56.
2. Kepes J.J. Presidential address: the histopathology of 
meningiomas. A reflection of origins and expected 
 behavior? J Neuropathol Exp Neurol. 1986; 45:95–107.
3. O’Rahilly R, F. Muller. The meninges in human develop-
ment. J Neuropathol Exp Neurol. 1986; 45:588–608.
4. Dziuk TW, Woo S, Butler EB, Thornby J, Grossman R, 
Dennis WS, Lu H, Carpenter LS, Chiu JK. Malignant 
meningioma: an indication for initial aggressive surgery 
and adjuvant radiotherapy. J Neurooncol. 1998; 37:177–88.
5. Morantz RA, Wara WW. Gamma Knife Radiosurgery in 
the Treatment of Brain Tumors. Cancer Control. 1995; 
2:300–308.
Oncotarget17603www.impactjournals.com/oncotarget
6. Coke CC, Corn BW, Werner-Wasik M, Xie Y, Curran WJ Jr. 
Atypical and malignant meningiomas: an outcome report of 
seventeen cases. J Neurooncol. 1998; 39:65–70.
7. Hug EB, Devries A, Thornton AF, Munzenride JE, 
Pardo FS, Hedley-Whyte ET, Bussiere MR, Ojemann R. 
Management of atypical and malignant meningiomas: 
role of high-dose, 3D-conformal radiation therapy. 
J Neurooncol. 2000; 48:151–60.
8. Moazzam AA, Wagle N, Zada G. Recent developments 
in chemotherapy for meningiomas: a review. Neurosurg 
Focus. 2013; 35:E18.
9. Kotipatruni RP, Ferraro DJ, Ren X, Vanderwaal RP, 
Thotala DK, Hallahan DE, Jaboin JJ. NDRG, the N-Myc 
downstream regulated gene, is important for cell survival, 
tumor invasion and angiogenesis in meningiomas. Integr 
Biol (Camb). 2012; 4:1185–97.
10. Zhou RH, Kokame K, Tsukamoto Y, Yutani C, Kato H, 
Miyata T. Characterization of the human NDRG gene 
 family: a newly identified member, NDRG4, is specifically 
expressed in brain and heart. Genomics. 2001; 73:86–97.
11. Qu X, Zhai Y, Wei H, Zhang C, Xing G, Yu Y, He F. 
Characterization and expression of three novel differentia-
tion-related genes belong to the human NDRG gene family. 
Mol Cell Biochem. 2002; 229:35–44.
12. Hwang J, Kim Y, Kang HB, Jaroszewski L, Deacon AM, 
Lee H, Choi WC, Kim KJ, Kim CH, Kang BS, Lee JO, 
Oh TK, Kim JW, Wilson IA, Kim MH. Crystal structure 
of the human N-Myc downstream-regulated gene 2 protein 
provides insight into its role as a tumor suppressor. J Biol 
Chem. 2011; 286:12450–60.
13. Benesh EC, Miller PM, Pfaltzgraff ER, Grega-Larson NE, 
Hager HA, Sung BH, Qu X, Baldwin HS, Weaver AM, 
Bader DM. Bves and NDRG4 regulate directional epicar-
dial cell migration through autocrine extracellular matrix 
deposition. Mol Biol Cell. 2013; 24:3496–510.
14. Shimono A, Okuda T, Kondoh H. N-myc-dependent repres-
sion of ndr1, a gene identified by direct subtraction of whole 
mouse embryo cDNAs between wild type and N-myc 
mutant. Mech Dev. 1999; 83:39–52.
15. Liu W, Xing F, Iiizumi-Gairani M, Okuda H, Watabe M, 
Pai SK, Pandey PR, Hirota S, Kobayashi A, Mo YY, 
Fukuda K, Li Y, Watabe K. N-myc downstream regulated 
gene 1 modulates Wnt-beta-catenin signalling and pleiotropi-
cally suppresses metastasis. EMBO Mol Med. 2012; 4:93–108.
16. Mao Z, Sun J, Feng B, Ma J, Zang L, Dong F, Zhang D, 
Zheng M. The metastasis suppressor, N-myc downregu-
lated gene 1 (NDRG1), is a prognostic biomarker for human 
colorectal cancer. PLoS One. 2013; 8:e68206.
17. Choi SC, Kim KD, Kim JT, Kim JW, Yoon DY, Choe YK, 
Chang YS, Paik SG, Lim JS. Expression and regulation of 
NDRG2 (N-myc downstream regulated gene 2) during the 
differentiation of dendritic cells. FEBS Lett. 2003; 553:413–8.
18. Sugiki T, Murakami M, Taketomi Y, Kikuchi-Yanoshita R, 
Kudo I. N-myc downregulated gene 1 is a phosphorylated 
protein in mast cells. Biol Pharm Bull. 2004; 27:624–7.
19. Kyuno J, Fukui A, Michiue T, Asashima M. Identification 
and characterization of Xenopus NDRG1. Biochem 
Biophys Res Commun. 2003; 309:52–7.
20. Nakada N, Hongo S, Ohki T, Maeda A, Takeda M. 
Molecular characterization of NDRG4/Bdm1 protein 
isoforms that are differentially regulated during rat brain 
development. Brain Res Dev Brain Res. 2002; 135:45–53.
21. Melotte V, Qu X, Ongenaert M, van Criekinge W, de 
Bruine AP, Baldwin HS, van Engeland M. The N-myc 
downstream regulated gene (NDRG) family: diverse func-
tions, multiple applications. FASEB J. 2010; 24:4153–66.
22. Ohki T, Hongo S, Nakada N, Maeda A, Takeda M. 
Inhibition of neurite outgrowth by reduced level of NDRG4 
protein in antisense transfected PC12 cells. Brain Res Dev 
Brain Res. 2002; 135:55–63.
23. Takahashi K, Yamada M, Ohata H, Honda K, Yamada M. 
Ndrg2 promotes neurite outgrowth of NGF-differentiated 
PC12 cells. Neurosci Lett. 2005; 388:157–62.
24. Hongo S, Watanabe T, Takahashi K, Miyazaki A. Ndrg4 
enhances NGF-induced ERK activation uncoupled with 
Elk-1 activation. J Cell Biochem. 2006; 98:185–93.
25. Li Y, Xu N, Cai L, Gao Z, Shen L, Zhang Q, Hou W, Zhong 
H, Wang Q, Xiong L. NDRG2 is a novel p53-associated 
regulator of apoptosis in C6-originated astrocytes exposed 
to oxygen-glucose deprivation. PLoS One. 2013; 8:e57130.
26. Liu N, Wang L, Li X, Yang Q, Liu X, Zhang J, Zhang J, 
Wu Y, Ji S, Zhang Y, Yang A, Han H, Yao L. N-Myc 
downstream-regulated gene 2 is involved in p53-mediated 
apoptosis. Nucleic Acids Res. 2008; 36:5335–49.
27. Yamamoto H, Kokame K, Okuda T, Nakajo Y, 
Yanamoto H, Miyata T. NDRG4 protein-deficient mice 
exhibit spatial learning deficits and vulnerabilities to cere-
bral ischemia. J Biol Chem. 2011; 286:26158–65.
28. Melotte V, Lentjes MH, van den Bosch SM, Hellebrekers 
DM, de Hoon JP, Wouters KA, Daenen KL, Partouns-
HendriksI E, Stessels F, Louwagie J, Smits KM, 
Weijenberg MP, Sanduleanu S, Khalid-de Bakker CA, 
Oort FA, Meijer GA, Jonkers DM, Herman JG, de 
Bruine AP, van Engeland M. N-Myc downstream-regulated 
gene 4 (NDRG4): a candidate tumor suppressor gene and 
potential biomarker for colorectal cancer. J Natl Cancer 
Inst. 2009; 101:916–27.
29. Schilling SH, Hjelmeland AB, Radiloff DR, Liu IM, 
Wakeman TP, Fielhauer JR, Foster EH, Lathia JD, Rich JN, 
Wang XF, Datto MB. NDRG4 is required for cell cycle pro-
gression and survival in glioblastoma cells. J Biol Chem. 
2009; 284:25160–9.
30. Merino JJ, Cordero-Campana MI. Molecular bases of the 
programmed cell death process: implications of tumor sup-
pressor protein p53 and other proteins in the control of cell 
cycle. Mechanisms of apoptotic action. Review. Invest Clin. 
1998; 39:323–58.
31. Laptenko O, Prives C. Transcriptional regulation by p53: 
one protein, many possibilities. Cell Death Differ. 2006; 
13:951–61.
Oncotarget17604www.impactjournals.com/oncotarget
32. Nagashima G, Aoyagi M, Yamamoto M, Yamamoto S, 
Wakimoto H, Ohno K, Yamamoto K, Hirakawa K. P53 overex-
pression and proliferative potential in malignant meningiomas. 
Acta Neurochir (Wien). 1999; 141:53–61. discussion 60–1.
33. Levine AJ. p53, the cellular gatekeeper for growth and divi-
sion. Cell. 1997; 88:323–31.
34. Chipuk JE, Fisher JC, Dillon CP, Kriwacki RW, Kuwana T, 
Green DR. Mechanism of apoptosis induction by inhibition 
of the anti-apoptotic BCL-2 proteins. Proc Natl Acad Sci 
 U S A. 2008; 105:20327–32.
35. Adams JM, Cory S. The Bcl-2 protein family: arbiters of 
cell survival. Science. 1998; 281:1322–6.
36. Kroemer G, Reed JC. Mitochondrial control of cell death. 
Nat Med. 2000; 6:513–9.
37. Malet G, Martin AG, Orzaez M, Vicent MJ, Masip I, 
Sanclimens G, Ferrer-Montiel A, Mingarro I, Messeguer A, 
Fearnhead HO, Perez-Paya E. Small molecule inhibitors of 
Apaf-1-related caspase- 3/-9 activation that control mitochon-
drial-dependent apoptosis. Cell Death Differ. 2006; 13:1523–32.
38. McCaffrey AP, Meuse L, Pham TT, Conklin DS, 
Hannon GJ, Kay MA. RNA interference in adult mice. 
Nature. 2002; 418:38–9.
39. Dirven CM, Grill J, Lamfers ML, Van der Valk P, 
Leonhart AM, Van Beusechem VW, Haisma HJ, 
Pinedo HM, Curiel DT, Vandertop WP, Gerritsen WR. 
Gene therapy for meningioma: improved gene delivery with 
targeted adenoviruses. J Neurosurg. 2002; 97:441–9.
40. Kim JT, Kim JW, Kang YH, Kim KD, Lee SJ, Choi SC, 
Kim KS, Chae SK, Kim JW, Lim JS, Lee HG. NDRG2 and 
PRA1 interact and synergistically inhibit T-cell factor/beta-
catenin signaling. FEBS Lett. 2012; 586:3962–8.
41. Ding W, Zhang J, Yoon JG, Shi D, Foltz G, Lin B. NDRG4 is 
downregulated in glioblastoma and inhibits cell proliferation. 
OMICS: a journal of integrative biology. 2012; 16:263–7.
42. Haga N, Fujita N, Tsuruo T. Tsuruo, Mitochondrial aggre-
gation precedes cytochrome c release from mitochondria 
during apoptosis. Oncogene. 2003; 22:5579–85.
43. Galluzzi L, Vitale I, Abrams JM, Alnemri ES, Baehrecke EH, 
Blagosklonny MV, Dawson TM, Dawson VL, El-Deiry WS, 
Fulda S, Gottlieb E, Green DR, Hengartner MO, Kepp O, 
Knight RA, Kumar S, Lipton SA, Lu X, Madeo F, 
Malorni W, Mehlen P, Nunez G, Peter ME, Piacentini M, 
Rubinsztein DC, Shi Y, Simon HU, Vandenabeele P, 
White E, Yuan J, Zhivotovsky B, Melino G, Kroemer G. 
Molecular definitions of cell death subroutines: recommen-
dations of the Nomenclature Committee on Cell Death. Cell 
Death Differ. 2012; 19:107–20.
44. Murphy AC, Weyhenmeyer B, Schmid J, Kilbride SM, 
Rehm M, Huber HJ, Senft C, Weissenberger J, Seifert V, 
Dunst M, Mittelbronn M, Kogel D, Prehn JH, Murphy BM. 
Activation of executioner caspases is a predictor of progres-
sion-free survival in glioblastoma patients: a systems medi-
cine approach. Cell Death Dis. 2013; 4:e629.
45. Porter PL, Gown AM, Kramp SG, Coltrera MD. 
Widespread p53 overexpression in human malignant 
tumors. An immunohistochemical study using methacarn-
fixed, embedded tissue. Am J Pathol. 1992; 140:145–53.
46. Miyashita T, Krajewski S, Krajewska M, Wang HG, 
Lin HK, Liebermann DA, Hoffman B, Reed JC. Tumor sup-
pressor p53 is a regulator of bcl-2 and bax gene expression 
in vitro and in vivo. Oncogene. 1994; 9:1799–805.
47. Yin C, Knudson CM, Korsmeyer SJ, Van Dyke T. Bax 
suppresses tumorigenesis and stimulates apoptosis in vivo. 
Nature. 1997; 385:637–40.
48. Findley HW, Gu L, Yeager AM, Zhou M. Expression and 
regulation of Bcl-2, Bcl-xl, and Bax correlate with p53 sta-
tus and sensitivity to apoptosis in childhood acute lympho-
blastic leukemia. Blood. 1997; 89:2986–93.
49. Mihara M, Erster S, Zaika A, Petrenko O, Chittenden T, 
Pancoska P, Moll UM. p53 has a direct apoptogenic role at 
the mitochondria. Mol Cell. 2003; 11:577–90.
50. Sasi N, Hwang M, Jaboin J, Csiki I, Lu B. Regulated cell 
death pathways: new twists in modulation of BCL2 family 
function. Mol Cancer Ther. 2009; 8:1421–9.
51. Berns K, Hijmans EM, Mullenders J, Brummelkamp TR, 
Velds A, Heimerikx M, Kerkhoven RM, Madiredjo M, 
Nijkamp W, Weigelt B, Agami R, Ge W, Cavet G, 
Linsley PS, Beijersbergen RL, Bernards R. A large-scale 
RNAi screen in human cells identifies new components of 
the p53 pathway. Nature. 2004; 428:431–7.
52. Nakasu S, Nakajima M, Nakazawa T, Nakasu Y, Handa J. 
p53 accumulation and apoptosis in embolized meningio-
mas. Acta Neuropathol. 1997; 93:599–605.
53. Chipuk JE, Kuwana T, Bouchier-Hayes L, Droin NM, 
Newmeyer DD, Schuler M, Green DR. Direct activa-
tion of Bax by p53 mediates mitochondrial membrane 
 permeabilization and apoptosis. Science. 2004; 303:1010–4.
54. Miyashita T, Reed JC. Tumor suppressor p53 is a direct 
transcriptional activator of the human bax gene. Cell. 1995; 
80:293–9.
55. Luu Y, Bush J, Cheung KJ Jr, Li G. The p53 stabilizing 
compound CP-31398 induces apoptosis by activating the 
intrinsic Bax/mitochondrial/caspase-9 pathway. Exp Cell 
Res. 2002; Jun 10;276:214–22.
56. Stein S, Thomas EK, Herzog B, Westfall MD, 
Rocheleau JV, Jackson RS 2nd, Wang M, Liang P. NDRG1 
is necessary for p53-dependent apoptosis. J Biol Chem. 
2004; 279:48930–40.
57. Stewart SA, Dykxhoorn DM, Palliser D, Mizuno H, Yu EY, 
An DS, Sabatini DM, Chen IS, Hahn WC, Sharp PA, 
Weinberg RA, Novina CD. Lentivirus-delivered stable gene 
silencing by RNAi in primary cells. RNA. 2003; 9:493–501.
58. Baekelandt V, Eggermont K, Michiels M, Nuttin B, 
Debyser Z. Optimized lentiviral vector production and puri-
fication procedure prevents immune response after trans-
duction of mouse brain. Gene Ther. 2003; 10:1933–40.
